Alzheimer's and Parkinson's Diseases: Expected Economic Impact on Europe-A Call for a Uniform European Strategy

Journal of Alzheimer's Disease

Volumn 54, Issue 3, 2016, Pages 1123-1133

  Maresova, Petra ^a   Klimova, Blanka ^a   Novotny, Michal ^a,b   Kuca, Kamil ^a,b  

^a UNIVERSITY OF HRADEC KRALOVE   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Alzheimer's disease; costs; economic burden; Europe; Parkinson's disease

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; DEMENTIA; ECONOMIC ASPECT; EUROPE; HEALTH CARE COST; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; AGED; COST OF ILLNESS; ECONOMICS; FEMALE; MALE; MORTALITY; TRENDS; VERY ELDERLY;

NEUROPROTECTIVE AGENT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COST OF ILLNESS; EUROPE; FEMALE; HUMANS; MALE; MORTALITY; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RETROSPECTIVE STUDIES;

EID: 84990051036     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160484     Document Type: Article

References (34)

1. Maresova P, Mohleska H, Kuca K (2015) Social and family load of Alzheimer's disease. appl Econ 48, 1936-1948.
2. Mohelska H, Maresova PM, Valis M, Kuca K (2015) Alzheimer's disease and its treatment costs: Case study in the Czech Republic. Neuropsychiatr Dis Treat 11, 2349-2354.
3. Aging report: Europe needs to prepare for growing older. http://ec. europa. eu/economy finance/articles/structural reforms/2012-05-15 ageing report en. htm. Last updated 2012, Accessed on July 9, 2015.
4. Kuca K, Soukup O, Maresova P, Korabecny J, Nepovimova E, Klimova B, Honegr J, Ramalho TC, Franca TCC (2016) Current approaches against Alzheimer's disease in clinical trials. J Med Chem 27, 641-649.
5. Shivanand P (2009) Review on Alzheimer's disease: Its cause, symptoms, and treatment at worldwide. Int J Appl Biol Pharm 1, 12-120.
6. World Health Ranking. http://www. worldlifeexpectancy. com/cause-of-death/alzheimers-dementia/by-country/. Last updated 2015, Accessed on July 9, 2015.
7. Klimova B, Kuca, K (2015) Alzheimer's disease: Potential preventive, non-invasive, intervention strategies in lowering the risk of cognitive decline-a review study. J Appl Biomed 13, 257-261.
8. Klimova B, Maresova P, Kuca K (2016) Assistive technologies in managing language disorders in dementia. Neuropsychiatr Dis Treat 12, 533-540.
9. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. Mov Disord 23, 837-844.
10. Lees AJ, Hardy J, Revesz T (2009) Parkinson's disease. Lancet 373, 2055-2066.
11. Zemek F, Drtinova L, Nepovimova E, Sepsova V, Korabecny J, Klimes J, Kuca K (2014) Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf 13, 759-774.
12. Nepovimova E, Uliassi E, Korabecny J, Peña-Altamira LE, Samez S, Pesaresi A, Garcia GE, Bartolini M, Andrisano V, Bergamini C, Fato R, Lamba D, Roberti M, Kuca K, Monti B, BolognesiM(2014) Multitarget drug design strategy: Quinone-tacrine hybrids designed to block amyloid- aggregation and to exert anticholinesterase and antioxidant effects. J Med Chem 57, 8576-8589.
13. SUKL. http://www. sukl. cz/modules/medication/search. php Last updated 2016, Accessed on April 9, 2016.
14. WHO. aTC/DDD Index 2016. http://www. whocc. no/atc ddd index/ Last updated 2016, Accessed on April 9, 2016.
15. ValisM(2014) Duodopa u pokrocile Parkinsonovy nemoci. [Duodopa in advanced Parkinson's disease in clinical practice-a case report. ] Neurol Praxi 15, 210-212.
16. NINDS. http://www. ninds. nih. gov/disorders/deep brain stimulation/deep brain stimulation. htm Last updated 2016, Accessed on April 9, 2016.
17. Reeder CE (1995) Overview of pharmacoeconomics and pharmaceutical outcomes evaluations. am J Health Syst-Pharm 52(Suppl 4), S5-S8.
18. Eisenberg JM (1989) Clinical economics: A guide to the economic analysis of clinical practices. JAMA 262, 2879-2886.
19. Getsios D, Blume S, Ishak Kj Maclaine G, Hernández L. (2012) An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom. alzheimers Dement 8, 22-30.
20. Travnickova K (2013) Economic analysis of the costs of treatment and care of patients with Alzheimer's disease. Economics and Management in Health Care: 3rd year: Proceedings of the student scientific conference organized by the Department of Biomedical Technology. 2013. Prague Czech Republic, pp. 205-212.
21. Gervès Ch, Chauvin P, Bellanger M (2014) Evaluation of full costs of care for patients with Alzheimer's disease in France: The predominant role of informal care. Health Policy 116, 114-122.
22. Schwarzkopf L, Menn P, Kunz S, Holle R, Lauterberg J, Marx P, Mehlig H, Wunder S, Leidl R, Donath C, Graessel E (2011) Costs of care for dementia patients in community setting: An analysis for mild and moderate disease stage. Value Health 14, 827-835.
23. Winter Y, von Campenhausen S, Brozova H, Skoupa J, Reese JP, Bötzel K, Eggert K, Oertel WH, Dodel R, RuzickaE. (2010) Costs of Parkinson's disease in Eastern Europe: ACzech cohort study. Parkinsonism Relat Disord 16, 51-56.
24. Winter Y, Campenhausen S, Reese JP, Balzer-Geldsetzer M, Longo K, Spiga G, Boetzel K, Eggert K, Oertel WH, Dodel R, Barone P (2010) Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: An Italian cohort study. Neurodegenerative 7, 365-372.
25. Spottke AE, Reuter M, Machat O, Bornschein B, Campenhausen S, Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm G, Dodel R (2005) Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 23, 817-836.
26. Hagell P, Nordling S, Reimer J, Grabowski M, Persson U (2002) Resource utilisation and costs in a Swedish Cohort of patients with Parkinson's disease. Mov Disord 17, 1213-1220.
27. Saloni T (2013) Alzheimer disease and other dementias. Background Paper 6. 11. 2. http://www. who. int/medicines/ areas/priority medicines/BP6 11Alzheimer. pdf Last updated 2013, Accessed on April 9, 2016.
28. Braak H, Del Tredici K (2012) Where, when, and in what form does sporadic Alzheimer disease begin Curr Opin Neurol 25, 708-174.
29. Alzheimer's Society. Demography. https://www. alzhei mers. org. uk/site/scripts/documents info. phpdocumentID =412 Last updated 2014, Accessed on April 9, 2016.
30. Alzheimer's Society. World Alzheimer Report 2015 The Global Impact of Dementia an analysis of prevalence, Incidence, cost and trends. https://www. alz. co. uk/ research/WorldAlzheimerReport2015. pdf. Last updated 2016, Accessed on April 9, 2016.
31. WHO. Health Topics. http://www. euro. who. int/en/home. Last updated 2013, Accessed on April 9, 2016.
32. Wimo A, Winblad B, Jönsson L (2010) The worldwide societal costs of dementia: Estimates for 2009. alzheimers Dement 6, 98-103.
33. Wimo A. Cost of illness and burden of dementia in Europe-Prognosis to 2030. alzheimer Europe. http:// alzheimer-europe. org/Research/European-Collaborationon-Dementia/Cost-of-dementia/Prognosis-to-2030 Accessed on July 9, 2015.
34. Alzheimer Europe. France National Dementia Strategies 2013. http://www. alzheimer-europe. org/Policy-in-Practice 2/National-Dementia-Plans/France Last updated 2016, Accessed on April 9, 2016.